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Dear Editor,
The Luminex human leukocyte antigen (HLA) single-antigen 
bead assay (SABA) was developed as a sensitive and specific 
assay to detect HLA antibodies [1]. However, false positive reac-
tions may occur in the SABA due to the effect of medications 
such as high-dose intravenous immunoglobulin, anti-thymocyte 
globulin, and anti-CD20 or the presence of antibodies against 
denatured HLA [1]. Several approaches to overcome this issue 
have been proposed, including the use of a pretreatment re-
agent that adsorbs non-specific antibodies or drugs and acid 
treatment to distinguish specific antibodies against denatured 
class I HLA [2]. The use of acid treatment and iBead (single-
antigen flow bead) has largely resolved the problem caused by 
antibodies against denatured class I HLA [2, 3]. However, there 
is no method for distinguishing antibodies against denatured 
class II HLA. Antibodies against denatured class II HLA have 
been detected at a frequency of 11% in healthy male donors 
[4]. Pan-HLA-DR reactivity is a pattern typically observed in the 
presence of antibodies against denatured class II HLA [5]. An-
other study found allelic bead reactions with HLA-DRB1*09:01, 
DRB3*01:01, DRB3*02:02, DRB3*03:01, DPB1*02:01, 
DPB1*20:01, and DPB1*28:01 for antibody reaction against 
denatured class II HLA [6]. 
Here, we report a case of false positive reaction with an anti-
body against denatured class II HLA, which showed different 
reactivities in screening and while using identification beads 
and SABA kits from different manufacturers. This study was ap-
proved by the Institutional Review Board of Severance Hospital, 
Seoul, Korea (4-2019-0984).
A 52-year-old female with end-stage renal disease caused by 
membranous nephropathy visited Severance hospital for her 
first kidney transplant in April 2016. She had no history of trans-
fusion or desensitization, such as high-dose intravenous immu-
noglobulin, anti-thymocyte globulin, or anti-CD20, and her preg-
nancy history was unknown. The patient did not provide in-
formed consent specific to this study but did provide consent 
for the test and signed a comprehensive agreement on the po-
tential use of the donated sample for research purposes. 
Genomic DNA was extracted from the peripheral blood using 
the QuickGene-Mini80 DNA Isolation System (Fujifilm, Tokyo, 
Japan). HLA typing was performed without delay using Life-
codes HLA SSO Typing Kits (Immucor Transplant Technology, 
Stamford, CT, USA), which revealed HLA-A*11, *33; B*27, 
*54; DRB1*08, *14, DQB1*05, *08. The result of the initial 
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HLA antibody screening (LABScreen Mixed, One Lambda, Ca-
noga Park, CA, USA) was negative for class II HLA antibodies. 
However, SABA using LABScreen SAB class II kit (One Lambda) 
showed strong pan-positive reactions [mean fluorescence inten-
Fig. 1. Reactivity patterns of class II HLA antibody assays. (A) LABScreen SAB class II (One Lambda, Canoga Park, LA, USA) SABA show-
ing pan-HLA-DR positivity. Self-HLA-DR antigens are indicated by red circles. (B) Lifecodes class II SABA (Immucor, Stamford, CT, USA) 
showing positivity for HLA-DR51 and -DR9. (C) PRA Identification Bead Reaction (LABScreen PRA, One Lambda) showing weak positivity 
for HLA-DR51,  DR15, and  DR16.
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Recombinant HLA molecules coated on each bead
HLA antigens coated on each bead
Recombinant HLA molecules coated on each bead
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Table 1. Assignment of class II HLA antibody specificity according to bead type and manufacturer
Kit used Class II HLA antibody specificity identified in each essay* Source of antigen
One Lambda SABA (LABScreen SAB) Strong:  DR1, DR4, DR7, DR8, DR9, DR10, DR11, DR12, DR13, DR14, DR15, DR16, 
DR17, DR18, DR51, DR52, DR52, DR103, DQ2, DQ4, DQ5, DQ6, DQA1*01:01, 
DQA1*01:02, DQA1*03:01, DQA1*04:01
Moderate: DQ8, DQ9 
Weak: DQA1*02:01
Recombinant HLA molecule
Immucor SABA (Lifecodes LSA) Weak: DR51, DR103, DR9 Recombinant HLA molecule
One Lambda screening (LABscreen Mixed) Negative for class II HLA antibodies Purified human HLA
One Lambda identification (LABscreen PRA) Weak: DR15, DR16, DR51 Purified human HLA
*Strong, >10,000 MFI; Moderate, 3,000-9,999 MFI; Weak, 1,000-2,999 MFI. 
Abbreviations: HLA, human leukocyte antigen; PRA, panel reactive antibody; MFI, mean fluorescence intensity; SABA, single antigen bead assay.
sity (MFI) >10,000] against all HLA-DR, including self-HLA an-
tigens (Fig. 1A). The SABA results were not changed in the 
presence of the adsorption beads provided by manufacturers. 
The patient’s serum was subsequently retested using a different 
SABA kit (Lifecodes LSA Class II Single Antigen Kit, Immucor), 
and this test revealed weak positive reactions (MFI 1,000-2,000) 
against DR9 and DR51 (Fig. 1B). The LABScreen panel reac-
tive antibody (PRA) (One Lambda) assay, in which the beads 
are coated with purified human HLA, showed positive reactions 
against DR15, DR16, and DR51 (Fig. 1C). All assays were per-
formed using the same initial serum, and the results were ad-
justed according to the results of the simultaneously tested neg-
ative control serum provided along with the kit.
Serologic evidence for the presence of donor-specific antibod-
ies is an important criterion for Banff classification [7]. However, 
the presence of antibodies against denatured HLA has no clini-
cal impact [8]. A previous study found antibodies against dena-
tured class I HLA in 39% of patients on the kidney transplant 
waiting list [3]. These antibodies were not considered to be tar-
geting intact cells, but rather targeting the heavy chains of HLA 
without β2-microglobulin, peptide, or cryptic antigens, as well as 
the polystyrene microbead itself [2, 4, 9]. Such unexpected an-
tigenic targets may become exposed by conformational changes 
of HLA molecules induced by purification and bead coating of 
single-clone allelic HLA [2, 9], eventually resulting in false posi-
tive antibody reactions. Antibodies against denatured class II 
HLA have been associated with the female gender and systemic 
lupus erythematous [6]; by contrast, our patient was diagnosed 
as having membranous nephropathy.
In the present case, different HLA antibody reactions were 
observed with two SABA kits from different manufacturers 
(LABScreen, One Lambda and Lifecodes, Immucor). Antigenic 
coating process was not clearly described on the manufacturer’s 
insert information. Immucor SABA did not show pan-DR reac-
tivity with the sample that showed false positive reaction in One 
Lambda SABA (Table 1). 
In this study, the screening (LABScreen Mixed) showed no 
antibody reactions and identification beads (LABScreen PRA) 
demonstrated weak positive reactions with HLA-DR15, -DR16, 
and -DR51 (Table 1). Both beads were coated with purified hu-
man HLA. However, the negative screening results may be due 
to the low sensitivity of the assay because of multiple class II 
HLA antigen beads being shared on a total of five beads. In ad-
dition, the sensitivity of an identification assay including class II 
HLA antigens on each bead could be lower than that of SABAs. 
For this reason, false positive reactions due to weak antibodies 
could not be demonstrated using screening or identification 
beads alone. 
Flow-cytometric cross-matching to lymphocytes with known 
HLA antigens is another strategy to overcome false positive re-
actions. However, we could not perform any cross-matching 
tests, which is the major limitation of this study. Despite this lim-
itation, our findings show that false positive reactions with anti-
bodies against denatured class II HLA might differ according to 
the different SABA kits. This suggests an alternative approach 
to overcome false positivity in SABA caused by antibodies 
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